Evidence map›Paper›PMID 29162058›Full record

Trial reportBMC neurology2017

Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Ilse M Nauta, Anne E M Speckens, Roy P C Kessels, Jeroen J G Geurts, Vincent de Groot, Bernard M J Uitdehaag, Luciano Fasotti, Brigit A de Jong

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Memory rehabilitation for people with multiple sclerosis.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ilse M NautaDepartment of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands. i.nauta1@vumc.nl.
Anne E M SpeckensDepartment of Psychiatry, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, the Netherlands.
Roy P C KesselsDonders Institute for Brain, Cognition and Behaviour, Radboud University, PO Box 9101, 6500 HB, Nijmegen, the Netherlands.
Jeroen J G GeurtsDepartment of Anatomy and Neurosciences, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.
Vincent de GrootDepartment of Rehabilitation Medicine, MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.
Bernard M J UitdehaagDepartment of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.
Luciano FasottiDonders Institute for Brain, Cognition and Behaviour, Radboud University, PO Box 9101, 6500 HB, Nijmegen, the Netherlands.
Brigit A de JongDepartment of Neurology, Amsterdam Neuroscience, MS Center Amsterdam, VU University Medical Center, PO Box 7057, 1007 MB, Amsterdam, the Netherlands.

Funding

Stichting MS Research 15-911
6 · The paper itself

Abstract

backgroundCognitive problems frequently occur in patients with multiple sclerosis (MS) and profoundly affect their quality of life. So far, the best cognitive treatment options for MS patients are a matter of debate. Therefore, this study aims to investigate the effectiveness of two promising non-pharmacological treatments: cognitive rehabilitation therapy (CRT) and mindfulness-based cognitive therapy (MBCT). Furthermore, this study aims to gain additional knowledge about the aetiology of cognitive problems among MS patients, since this may help to develop and guide effective cognitive treatments. METHODS/

designIn a dual-centre, single-blind randomised controlled trial (RCT), 120 MS patients will be randomised into one of three parallel groups: CRT, MBCT or enhanced treatment as usual (ETAU). Both CRT and MBCT consist of a structured 9-week program. ETAU consists of one appointment with an MS specialist nurse. Measurements will be performed at baseline, post-intervention and 6 months after the interventions. The primary outcome measure is the level of subjective cognitive complaints. Secondary outcome measures are objective cognitive function, functional brain network measures (using magnetoencephalography), psychological symptoms, well-being, quality of life and daily life functioning. DISCUSSION: To our knowledge, this will be the first RCT that investigates the effect of MBCT on cognitive function among MS patients. In addition, studying the effect of CRT on cognitive function may provide direction to the contradictory evidence that is currently available. This study will also provide information on changes in functional brain networks in relation to cognitive function. To conclude, this study may help to understand and treat cognitive problems among MS patients.

trial registrationThis trial was prospectively registered at the Dutch Trial Registration (number NTR6459 , registered on 31 May 2017).

Indexed as

CognitionCognitive Behavioral TherapyHumansMindfulnessMultiple SclerosisQuality of LifeSingle-Blind MethodTime FactorsTreatment OutcomeBrain networksCognitionCognitive rehabilitation therapyMindfulness-based cognitive therapyMultiple sclerosisRandomised controlled trial

Identifiers

PMID29162058
PMCPMC5698960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.